{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T16:21:53Z","timestamp":1791130913471,"version":"4.1.0"},"reference-count":98,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Statins are widely used crucial drugs for the primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD). Although generally well tolerated, statin intolerance can unfortunately limit statin use, with statin-associated muscle symptoms (SAMS) being the most common side effect associated with its discontinuation. Statin intolerance is an inability to tolerate a dose of statin required to sufficiently reduce an individual\u2019s cardiovascular risk, limiting the effective treatment of patients at risk of or with cardiovascular disease (CVD). Statin myopathy is a broad entity encompassing self-limited\/toxic and autoimmune aetiologies. As statins are a mainstay of therapy in those with or at risk for CVD and offer a mortality benefit, it is critical to determine whether one\u2019s symptoms are truly statin-associated before discontinuing the drug. This review article aims to provide an update on the epidemiology, pathophysiology, clinical features, diagnosis, evaluation and management of statin myopathy and to elucidate key differences between autoimmune and self-limited types.<\/jats:p>","DOI":"10.1093\/rheumatology\/keae284","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T20:51:41Z","timestamp":1717447901000},"page":"2648-2659","source":"Crossref","is-referenced-by-count":7,"title":["Breaking down statin myopathy: understanding the self-limited and autoimmune subtypes"],"prefix":"10.1093","volume":"63","author":[{"given":"Joel","family":"Wright","sequence":"first","affiliation":[{"name":"Department of Medicine, Englewood Hospital and Medical Center , Englewood, NJ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7150-7306","authenticated-orcid":false,"given":"Lisa","family":"Christopher-Stine","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine , Baltimore, MD,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"key":"2024100107550109400_keae284-B1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/CIRCRESAHA.118.312782","article-title":"Statin toxicity","volume":"124","author":"Ward","year":"2019","journal-title":"Circ Res"},{"key":"2024100107550109400_keae284-B2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/1744666X.2018.1440206","article-title":"Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations","volume":"14","author":"Selva-O\u2019Callaghan","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"2024100107550109400_keae284-B3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"key":"2024100107550109400_keae284-B4","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"2024100107550109400_keae284-B5","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1001\/archinte.165.22.2671","article-title":"Outcomes in 45 patients with statin-associated myopathy","volume":"165","author":"Hansen","year":"2005","journal-title":"Arch Intern Med"},{"key":"2024100107550109400_keae284-B6","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3949\/ccjm.81a.13158","article-title":"Identifying statin-associated autoimmune necrotizing myopathy","volume":"81","author":"Albayda","year":"2014","journal-title":"Cleve Clin J Med"},{"key":"2024100107550109400_keae284-B7","first-page":"1658","article-title":"Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial","volume":"2010","author":"Armitage","journal-title":"Lancet Lond Engl"},{"key":"2024100107550109400_keae284-B8","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nmd.2006.10.007","article-title":"Progressive myopathy with up-regulation of MHC-I associated with statin therapy","volume":"17","author":"Needham","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"2024100107550109400_keae284-B9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.21486","article-title":"Immune-mediated necrotizing myopathy associated with statins","volume":"41","author":"Grable-Esposito","year":"2010","journal-title":"Muscle Nerve Off J Am Assoc Electrodiagn Med"},{"key":"2024100107550109400_keae284-B10","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2024100107550109400_keae284-B11","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2024100107550109400_keae284-B12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2147\/TCRM.S197941","article-title":"Statin-associated autoimmune myopathy: current perspectives","volume":"16","author":"Tiniakou","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"2024100107550109400_keae284-B13","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jacc.2016.04.037","article-title":"Statin-induced anti-HMGCR-associated myopathy","volume":"68","author":"Basharat","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2024100107550109400_keae284-B14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3233\/JND-170282","article-title":"Anti-HMGCR myopathy","volume":"5","author":"Mohassel","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"2024100107550109400_keae284-B15","doi-asserted-by":"crossref","first-page":"adv00415","DOI":"10.2340\/00015555-3645","article-title":"Unusual skin involvement in statin-induced anti-HMGCR immune-mediated necrotizing myopathy","volume":"101","author":"Scard","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"2024100107550109400_keae284-B16","doi-asserted-by":"crossref","first-page":"102691","DOI":"10.1016\/j.jaut.2021.102691","article-title":"Cutaneous involvement in anti-HMGCR positive necrotizing myopathy","volume":"123","author":"Williams","year":"2021","journal-title":"J Autoimmun"},{"key":"2024100107550109400_keae284-B17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.5152\/eurjrheum.2020.20064","article-title":"A case of statin-associated immune-mediated necrotizing myopathy with atypical biopsy features","volume":"8","author":"Zaki","year":"2021","journal-title":"Eur J Rheumatol"},{"key":"2024100107550109400_keae284-B18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/mus.24642","article-title":"The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy","volume":"52","author":"Chung","year":"2015","journal-title":"Muscle Nerve"},{"key":"2024100107550109400_keae284-B19","article-title":"Myopathy with anti-HMGCR antibodies: perimysium and myofiber pathology","volume":"2015","author":"Alshehri","journal-title":"Neurol-Neuroimmunol Neuroinflamm"},{"key":"2024100107550109400_keae284-B20","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/mus.24541","article-title":"Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy","volume":"52","author":"Limaye","year":"2015","journal-title":"Muscle Nerve"},{"key":"2024100107550109400_keae284-B21","first-page":"787","article-title":"More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"56","author":"Tiniakou","year":"2017","journal-title":"Rheumatology"},{"key":"2024100107550109400_keae284-B22","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MD.0000000000000028","article-title":"Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin","volume":"93","author":"Allenbach","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"2024100107550109400_keae284-B23","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00415-021-10621-7","article-title":"Anti-HMGCR myopathy overlaps with dermatomyositis-like rash: a distinct subtype of idiopathic inflammatory myopathy","volume":"269","author":"Hou","year":"2022","journal-title":"J Neurol"},{"key":"2024100107550109400_keae284-B24","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/cns.13658","article-title":"Juvenile idiopathic inflammatory myopathies with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in a Chinese cohort","volume":"27","author":"Hou","year":"2021","journal-title":"CNS Neurosci Ther"},{"key":"2024100107550109400_keae284-B25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/rheumatology\/kew386","article-title":"Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies","volume":"56","author":"Liang","year":"2017","journal-title":"Rheumatology"},{"key":"2024100107550109400_keae284-B26","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/acr.23113","article-title":"Anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase autoantibodies are associated with DRB1. 07: 01 and severe myositis in pediatric myositis patients","volume":"69","author":"Kishi","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2024100107550109400_keae284-B27","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3899\/jrheum.160871","article-title":"Anti-HMGCR autoantibodies in juvenile idiopathic inflammatory myopathies identify a rare but clinically important subset of patients","volume":"44","author":"Tansley","year":"2017","journal-title":"J Rheumatol"},{"key":"2024100107550109400_keae284-B28","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bcp.12339","article-title":"Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review","volume":"78","author":"De Vera","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"2024100107550109400_keae284-B29","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Byty\u00e7i","year":"2022","journal-title":"Eur Heart J"},{"key":"2024100107550109400_keae284-B30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jacl.2017.01.006","article-title":"Statin-associated muscle symptoms\u2014managing the highly intolerant","volume":"11","author":"Backes","year":"2017","journal-title":"J Clin Lipidol"},{"key":"2024100107550109400_keae284-B31","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","article-title":"Statin-associated side effects","volume":"67","author":"Thompson","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2024100107550109400_keae284-B32","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2024100107550109400_keae284-B33","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.coph.2007.12.010","article-title":"New insights into mechanisms of statin-associated myotoxicity","volume":"8","author":"Sirvent","year":"2008","journal-title":"Curr Opin Pharmacol"},{"key":"2024100107550109400_keae284-B34","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1007\/s11606-021-06651-6","article-title":"The risk of muscular events among new users of hydrophilic and lipophilic statins: an observational cohort study","volume":"36","author":"Mueller","year":"2021","journal-title":"J Gen Intern Med"},{"key":"2024100107550109400_keae284-B35","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.phrs.2017.09.013","article-title":"The effect of lipophilicity and dose on the frequency of statin-associated muscle symptoms: a systematic review and meta-analysis","volume":"128","author":"Irwin","year":"2018","journal-title":"Pharmacol Res"},{"key":"2024100107550109400_keae284-B36","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"2024100107550109400_keae284-B37","doi-asserted-by":"crossref","first-page":"103304","DOI":"10.1016\/j.amsu.2022.103304","article-title":"Statin induced myopathy among patients attending the National Center for Diabetes, Endocrinology, & Genetics","volume":"74","author":"Abed","year":"2022","journal-title":"Ann Med Surg"},{"key":"2024100107550109400_keae284-B38","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0140-6736(22)01545-8","article-title":"Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials","volume":"400","author":"Reith","year":"2022","journal-title":"The Lancet"},{"key":"2024100107550109400_keae284-B39","doi-asserted-by":"crossref","first-page":"a2286","DOI":"10.1136\/bmj.a2286","article-title":"Statin induced myopathy","volume":"337","author":"Sathasivam","year":"2008","journal-title":"BMJ"},{"key":"2024100107550109400_keae284-B40","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-associated autoimmune myopathy","volume":"374","author":"Mammen","year":"2016","journal-title":"N Engl J Med"},{"key":"2024100107550109400_keae284-B41","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/RHU.0000000000000497","article-title":"Statin-associated autoimmune myopathy: a systematic review of 100 cases","volume":"23","author":"Nazir","year":"2017","journal-title":"JCR J Clin Rheumatol"},{"key":"2024100107550109400_keae284-B42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11926-018-0732-6","article-title":"Immune-mediated necrotizing myopathy","volume":"20","author":"Pinal-Fernandez","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"2024100107550109400_keae284-B43","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/art.42126","article-title":"Increased risk of statin-associated autoimmune myopathy among American Indians","volume":"74","author":"Wei","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2024100107550109400_keae284-B44","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/rheumatology\/keaa337","article-title":"Potential implications of six American Indian patients with myopathy, statin exposure and anti-HMGCR antibodies","volume":"60","author":"Close","year":"2021","journal-title":"Rheumatology"},{"issue":"Suppl. 2","key":"2024100107550109400_keae284-B45","doi-asserted-by":"crossref","first-page":"S325","DOI":"10.2337\/dcS13-2038","article-title":"Intolerance to statins: mechanisms and management","volume":"36","author":"Bitzur","year":"2013","journal-title":"Diabetes Care"},{"key":"2024100107550109400_keae284-B46","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/jcm6080075","article-title":"Statins, muscle disease and mitochondria","volume":"6","author":"Ramachandran","year":"2017","journal-title":"J Clin Med"},{"key":"2024100107550109400_keae284-B47","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/cvr\/cvy119","article-title":"Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence","volume":"114","author":"Brunham","year":"2018","journal-title":"Cardiovasc Res"},{"key":"2024100107550109400_keae284-B48","doi-asserted-by":"crossref","first-page":"575678","DOI":"10.3389\/fgene.2020.575678","article-title":"Pharmacogenetics of statin-induced myotoxicity","volume":"11","author":"Kee","year":"2020","journal-title":"Front Genet"},{"key":"2024100107550109400_keae284-B49","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/cpt.1557","article-title":"Genomewide association study of statin-induced myopathy in patients recruited using the UK clinical practice research datalink","volume":"106","author":"Carr","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"2024100107550109400_keae284-B50","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ana.24902","article-title":"Pathogenic role of anti\u2013signal recognition protein and anti\u20133-Hydroxy-3-methylglutaryl-C o A reductase antibodies in necrotizing myopathies: myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies","volume":"81","author":"Arouche-Delaperche","year":"2017","journal-title":"Ann Neurol"},{"key":"2024100107550109400_keae284-B51","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/acr.21671","article-title":"Increased frequency of DRB1 11: 01 in anti\u2013hydroxymethylglutaryl-coenzyme a reductase\u2013associated autoimmune myopathy","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2024100107550109400_keae284-B52","doi-asserted-by":"crossref","first-page":"103468","DOI":"10.1016\/j.autrev.2023.103468","article-title":"Anti-HMGCR immune-mediated necrotising myopathy: addressing the remaining issues","volume":"22","author":"Khoo","year":"2023","journal-title":"Autoimmun Rev"},{"key":"2024100107550109400_keae284-B53","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/03009742.2019.1672782","article-title":"Anti-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibody in necrotizing myopathy: treatment outcomes, cancer risk, and role of autoantibody level","volume":"49","author":"Aggarwal","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"2024100107550109400_keae284-B54","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/brain\/aww054","article-title":"High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody","volume":"139","author":"Allenbach","year":"2016","journal-title":"Brain"},{"key":"2024100107550109400_keae284-B55","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000290","article-title":"Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy","volume":"3","author":"Kadoya","year":"2016","journal-title":"Neurol-Neuroimmunol Neuroinflamm"},{"key":"2024100107550109400_keae284-B56","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41584-023-01045-w","article-title":"International guideline for idiopathic inflammatory myopathy-associated cancer screening: an international myositis assessment and clinical studies group (IMACS) initiative","volume":"19","author":"Oldroyd","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2024100107550109400_keae284-B57","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10557-017-6723-4","article-title":"The statin-associated muscle symptom clinical index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability","volume":"31","author":"Rosenson","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"2024100107550109400_keae284-B58","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jacl.2022.09.001","article-title":"Assessment and management of statin-associated muscle symptoms (SAMS): a clinical perspective from the National Lipid Association","volume":"17","author":"Warden","year":"2023","journal-title":"J Clin Lipidol"},{"key":"2024100107550109400_keae284-B59","first-page":"2522","article-title":"Frequency of checking creatine kinase in patients on statins with elevated transaminase for early detection of statin induced myopathy","volume":"74","author":"Nidhaan","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2024100107550109400_keae284-B60","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cca.2017.07.011","article-title":"Detection of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme a reductase by ELISA in a reference laboratory setting","volume":"472","author":"Jaskowski","year":"2017","journal-title":"Clin Chim Acta"},{"key":"2024100107550109400_keae284-B61","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/acr.20662","article-title":"Anti-HMG-CoA reductase antibodies are rare in statin users, including those with self-limited musculoskeletal side-effects","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2024100107550109400_keae284-B62","first-page":"1161"},{"key":"2024100107550109400_keae284-B63","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/BOR.0000000000000326","article-title":"Value of MRI in diagnostics and evaluation of myositis","volume":"28","author":"Pipitone","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"2024100107550109400_keae284-B64","first-page":"420","volume-title":"Semin Arthritis Rheum","author":"Day","year":"2019"},{"key":"2024100107550109400_keae284-B65","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11926-019-0807-z","article-title":"Diagnostic imaging of inflammatory myopathies: new concepts and a radiological approach","volume":"21","author":"Guimar\u00e3es","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"2024100107550109400_keae284-B66","doi-asserted-by":"crossref","first-page":"W323","DOI":"10.2214\/AJR.09.2698","article-title":"MRI in lipid-lowering agent\u2013associated myopathy: a retrospective review of 21 cases","volume":"194","author":"Peters","year":"2010","journal-title":"Am J Roentgenol"},{"key":"2024100107550109400_keae284-B67","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ecl.2022.01.004","article-title":"Safety of statins and nonstatins for treatment of dyslipidemia","volume":"51","author":"Newman","year":"2022","journal-title":"Endocrinol Metab Clin"},{"key":"2024100107550109400_keae284-B68","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cjca.2011.05.007","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference","volume":"27","author":"Mancini","year":"2011","journal-title":"Can J Cardiol"},{"key":"2024100107550109400_keae284-B69","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol."},{"key":"2024100107550109400_keae284-B70","doi-asserted-by":"crossref","first-page":"A908","DOI":"10.1016\/j.chest.2020.08.844","article-title":"Treatment resistant rhabdomyolysis: can steroids and plasmapheresis play a role?","volume":"158","author":"Islam","year":"2020","journal-title":"Chest"},{"key":"2024100107550109400_keae284-B71","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.12659\/AJCR.905196","article-title":"Short-term high-dose steroid therapy in a case of rhabdomyolysis refractory to intravenous fluids","volume":"18","author":"Zarlasht","year":"2017","journal-title":"Am J Case Rep"},{"key":"2024100107550109400_keae284-B72","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacl.2015.03.005","article-title":"Successful reintroduction of statin therapy after statin-associated rhabdomyolysis","volume":"9","author":"Simons","year":"2015","journal-title":"J Clin Lipidol"},{"key":"2024100107550109400_keae284-B73","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/BOR.0000000000000438","article-title":"Immune-mediated necrotizing myopathy associated with statins: history and recent developments","volume":"29","author":"Tiniakou","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"2024100107550109400_keae284-B74","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC International Workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14\u201316 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"2024100107550109400_keae284-B75","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMc1506163","article-title":"Intravenous immune globulin for statin-triggered autoimmune myopathy","volume":"373","author":"Mammen","year":"2015","journal-title":"N Engl J Med"},{"key":"2024100107550109400_keae284-B76","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13075-019-2093-6","article-title":"Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients","volume":"22","author":"Meyer","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2024100107550109400_keae284-B77","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1002\/art.34673","article-title":"Antibody levels correlate with creatine kinase levels and strength in anti\u20133-hydroxy-3-methylglutaryl-coenzyme A reductase\u2013associated autoimmune myopathy","volume":"64","author":"Werner","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2024100107550109400_keae284-B78","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1056\/NEJMc2031173","article-title":"N-of-1 trial of a statin, placebo, or no treatment to assess side effects","volume":"383","author":"Wood","year":"2020","journal-title":"N Engl J Med"},{"key":"2024100107550109400_keae284-B79","doi-asserted-by":"crossref","first-page":"n135","DOI":"10.1136\/bmj.n135","article-title":"Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials","volume":"372","author":"Herrett","year":"2021","journal-title":"BMJ"},{"key":"2024100107550109400_keae284-B80","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2125.2003.02044.x","article-title":"Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems","volume":"57","author":"Sinzinger","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"2024100107550109400_keae284-B81","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/JES.0b013e31826c169e","article-title":"Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes","volume":"40","author":"Parker","year":"2012","journal-title":"Exerc Sport Sci Rev"},{"key":"2024100107550109400_keae284-B82","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jacl.2017.07.003","article-title":"The effects of statins on exercise and physical activity","volume":"11","author":"Noyes","year":"2017","journal-title":"J Clin Lipidol"},{"key":"2024100107550109400_keae284-B83","doi-asserted-by":"crossref","first-page":"207","DOI":"10.5551\/jat.RV17030","article-title":"Diagnosis and management of statin intolerance","volume":"26","author":"Alonso","year":"2019","journal-title":"J Atheroscler Thromb"},{"key":"2024100107550109400_keae284-B84","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mus.20567","article-title":"Genetic risk factors associated with lipid-lowering drug-induced myopathies","volume":"34","author":"Vladutiu","year":"2006","journal-title":"Muscle Nerve Off J Am Assoc Electrodiagn Med"},{"key":"2024100107550109400_keae284-B85","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/mus.21074","article-title":"Statins may aggravate myasthenia gravis","volume":"38","author":"Oh","year":"2008","journal-title":"Muscle Nerve Off J Am Assoc Electrodiagn Med"},{"key":"2024100107550109400_keae284-B86","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/17482960802031092","article-title":"Are statin medications safe in patients with ALS?","volume":"9","author":"Zinman","year":"2008","journal-title":"Amyotroph Lateral Scler"},{"key":"2024100107550109400_keae284-B87","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/anr.1780320324","article-title":"The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis","volume":"32","author":"Goldman","year":"1989","journal-title":"Arthritis Rheum"},{"key":"2024100107550109400_keae284-B88","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/rheumatology\/33.2.199","article-title":"Simvastatin-associated dermatomyositis","volume":"33","author":"Khattak","year":"1994","journal-title":"Rheumatology"},{"key":"2024100107550109400_keae284-B89","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/pgmj.72.853.694","article-title":"Lovastatin-associated dermatomyositis","volume":"72","author":"Rodriguez-Garcia","year":"1996","journal-title":"Postgrad Med J"},{"key":"2024100107550109400_keae284-B90","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000101287","article-title":"Statins provoking melas syndrome","volume":"57","author":"Thomas","year":"2007","journal-title":"Eur Neurol"},{"key":"2024100107550109400_keae284-B91","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1365-2796.2005.01515.x","article-title":"Statin-disclosed acid maltase deficiency","volume":"258","author":"Voermans","year":"2005","journal-title":"J Intern Med"},{"key":"2024100107550109400_keae284-B92","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1016\/j.ajpath.2014.04.013","article-title":"Abnormal splicing of NEDD4 in myotonic dystrophy type 2: possible link to statin adverse reactions","volume":"184","author":"Screen","year":"2014","journal-title":"Am J Pathol"},{"key":"2024100107550109400_keae284-B93","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/archinte.166.14.1519","article-title":"Presymptomatic neuromuscular disorders disclosed following statin treatment","volume":"166","author":"Tsivgoulis","year":"2006","journal-title":"Arch Intern Med"},{"key":"2024100107550109400_keae284-B94","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.2147\/DDDT.S223153","article-title":"Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study","volume":"3","author":"Derosa","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"2024100107550109400_keae284-B95","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.amjcard.2007.06.030","article-title":"Effect of coenzyme Q10 supplementation on simvastatin-induced myalgia","volume":"100","author":"Young","year":"2007","journal-title":"Am J Cardiol"},{"key":"2024100107550109400_keae284-B96","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2014.12.016","article-title":"A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy","volume":"238","author":"Taylor","year":"2015","journal-title":"Atherosclerosis"},{"key":"2024100107550109400_keae284-B97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2022.10.013","article-title":"Comparative effects of low-dose rosuvastatin, placebo, and dietary supplements on lipids and inflammatory biomarkers","volume":"81","author":"Laffin","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2024100107550109400_keae284-B98","article-title":"Necrotizing myopathy with elevated anti-HMGCR antibodies following exposure to the supplement Bacopa","volume":"67","author":"Yaworski","year":"2022","journal-title":"Muscle Nerve"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae284\/58464456\/keae284.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/10\/2648\/59432834\/keae284.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/10\/2648\/59432834\/keae284.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T07:56:09Z","timestamp":1727769369000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/10\/2648\/7687073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":98,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,6,3]]},"published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae284","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,6,3]]}}}